Amgen receives EU approval for expanded paediatric indication for Mimpara

Amgen has announced that its secondary hyperparathyroidism (HPT) therapy Mimpara has been approved in Europe in an expanded paediatric indication.

The European Commission has authorised a new formulation of Mimpara for the treatment of secondary HPT in children aged three years and older with end?stage renal disease on maintenance dialysis therapy, in whom secondary HPT is not adequately controlled with standard of care therapy.

This decision was based on positive findings from studies Amgen began in 2007 to assess the use of Mimpara among this patient group, who currently have very few treatment options available to them.

Secondary HPT is a chronic and serious condition characterised by excessive secretion of parathyroid hormone by the parathyroid glands, in response to decreased renal function and impaired mineral metabolism in chronic kidney disease patients on haemodialysis.

It is often initially silent and asymptomatic, meaning the disease is frequently underdiagnosed and undertreated.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "We are pleased with today's approval and the opportunity to provide patients and healthcare providers with an important therapy."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.